Pfizer Inc. 10-Q Summary: Quarter Ended September 26, 2004
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 26, 2004, and the nine-month period ended on the same date. Pfizer Inc. is a global research-based pharmaceutical company. The reporting period reflects the full impact of the Pharmacia Corporation acquisition (completed April 2003) and includes the results of the Esperion Therapeutics acquisition (completed February 2004). The company operates through three primary segments: Pharmaceutical, Consumer Healthcare, and Animal Health.
Key Financial Metrics
| Metric (Nine Months Ended Sept 26, 2004) | Value (Millions) | Prior Year (Nine Months Ended Sept 28, 2003) |
|---|---|---|
| Revenues | $37,593 | $30,754 |
| Net Income | $8,536 | $3,308 |
| Diluted EPS | $1.12 | $0.46 |
| Operating Cash Flow | $10,350 | $7,329 |
| Total Debt | $18,814 | $14,573 |
| Cash & Short-Term Investments | $18,678 | $11,952 |
| Working Capital | $13,818 | $6,768 |
Note: Net Income includes $75 million from discontinued operations. Adjusted Income (non-GAAP) for the nine months was $11,751 million.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 22% year-over-year, driven by the inclusion of Pharmacia results for the full nine-month period (vs. partial in 2003), strong performance of key products (Lipitor, Celebrex, Bextra), and favorable foreign exchange rates.
- Profitability: Net income increased 158%. This surge is largely attributable to a significant reduction in non-cash merger-related in-process research and development (IPR&D) charges ($955 million in 2004 vs. $5,043 million in 2003) and gains from discontinued operations in the prior year ($2,285 million in 2003 vs. $48 million in 2004).
- Cost Structure: Cost of sales decreased 18% due to the absence of inventory fair-value step-up charges present in 2003. Selling, informational, and administrative expenses rose 17% due to Pharmacia integration and new product support.
- Debt and Liquidity: Total debt increased by $4.2 billion due to new issuances of senior unsecured notes ($1.45 billion in Feb 2004 and $1.0 billion in Sept 2004). However, liquidity remains strong with a current ratio of 1.55:1.
Guidance, Outlook, and Risks
- 2004 Guidance: Pfizer projects full-year 2004 Adjusted Income of $16.1–$16.3 billion and GAAP Net Income of $12.0–$12.2 billion. Diluted EPS is expected to be $1.58–$1.60 (GAAP) and $2.12–$2.14 (Adjusted).
- Outlook Factors: Future growth faces headwinds from patent expirations (Diflucan, Neurontin, Accupril, Zithromax) and generic competition. These are expected to be offset by new product launches (Caduet, Spiriva, Lyrica) and continued cost synergies from the Pharmacia merger.
- Legal and Contingencies:
- Asbestos Litigation: A $369 million pre-tax charge was recorded in Q3 to settle Quigley Company asbestos claims via a Chapter 11 reorganization plan.
- Patent Disputes: Generic versions of Neurontin (gabapentin) were launched "at risk" by competitors despite ongoing litigation. Pfizer launched its own generic version via Greenstone.
- Product Liability: Ongoing litigation regarding Rezulin (investigation closed Oct 2004), Hormone-Replacement Therapy, and Neurontin promotion practices.
- Unusual Items: The Q3 results included a $369 million litigation charge and $955 million in IPR&D charges (primarily for Esperion). Discontinued operations included gains from the sale of the Diagnostics, surgical ophthalmic, and certain consumer product lines.
Investor Verification Checklist
- Patent Expiration Impact: Verify the specific timeline and revenue exposure for major products losing exclusivity in 2005–2007 (Diflucan, Neurontin, Zoloft, Norvasc).
- Asbestos Settlement Finality: Confirm the status of court and claimant approval for the Quigley Chapter 11 reorganization plan to ensure the $369 million charge is final.
- Neurontin Litigation Status: Monitor the outcome of patent infringement suits against generic manufacturers (Ivax, Alpharma, Teva) and the impact of Pfizer's own generic launch.
- COX-2 Safety Data: Review ongoing clinical trial data for Celebrex and Bextra regarding cardiovascular safety, especially following the withdrawal of Vioxx.
- Adjusted Income Reconciliation: Scrutinize the non-GAAP "Adjusted Income" metric, specifically the add-backs for purchase accounting amortization and merger costs, to understand core operating performance.